• Gabriela Simonová, Josef Novotny, and Roman Liscák.
• Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic. gabriela.simonova@homolka.cz
• J. Neurosurg. 2005 Jan 1; 102 Suppl: 19-24.

ObjectThe authors sought to evaluate local tumor control, complications, and progression-free survival in patients harboring low-grade gliomas who were treated with Leksell gamma knife surgery (GKS).MethodsDuring a 6-year period 70 patients were treated for verified low-grade gliomas (Grade I or II) by GKS. Statistical analysis was based on 68 patients; two patients were lost to follow up. The median patient age was 17 years. The median target volume was 4200 mm.3 The median prescription dose was 25 Gy. The median number of fractions was five. Ninety-five percent of patients were treated in five daily fractions. Partial or complete tumor regression was achieved in 83% of patients with a median time to response of 18 months. There was moderate acute or late toxicity in not more than 5% of patients. In this series the progression-free survival was 92% at 3 years and 88% at 5 years.ConclusionsRelatively high local tumor control with minimal complications was achieved.

23 keywords...

hide…